A step by step guide to Lung Cancer procedure steps, including screening, biopsy methods, and imaging techniques for accurate diagnosis and staging.
Send us all your questions or requests, and our expert team will assist you.
Effective Diagnosis and Staging are the cornerstones of successful lung cancer treatment, guiding clinicians toward the most appropriate therapeutic pathway. For international patients seeking world‑class care, understanding how lung cancer is identified and classified can reduce uncertainty and improve outcomes. Each year, lung cancer accounts for more than 2 million new cases worldwide, making early and precise assessment essential.
This page provides a detailed overview of the diagnostic journey—from initial clinical evaluation to the final staging decision—tailored for patients traveling to Liv Hospital in Istanbul. We will discuss the role of imaging, tissue sampling, molecular profiling, and the multidisciplinary team that together create a personalized treatment plan.
Whether you are preparing for your first appointment or coordinating care from abroad, the information below will help you navigate the process with confidence.
The first step in Diagnosis and Staging is confirming the presence of a malignant lesion. Clinicians begin with a thorough medical history, focusing on smoking exposure, occupational hazards, and family cancer patterns. Physical examination may reveal signs such as persistent cough, chest pain, or unexplained weight loss.
Key diagnostic tools include:
When an abnormality is detected, the next objective is to obtain tissue for histopathological confirmation. Techniques such as bronchoscopy, endobronchial ultrasound (EBUS), and CT‑guided needle biopsy allow physicians to collect cells while minimizing patient discomfort.
At Liv Hospital, our interventional pulmonology team uses state‑of‑the‑art navigation bronchoscopy, which combines real‑time imaging with 3‑D mapping to reach peripheral lesions that were previously inaccessible. The obtained specimens are then examined by experienced pathologists who determine the cancer subtype (e.g., adenocarcinoma, squamous cell carcinoma, small‑cell lung cancer) and grade, both critical for subsequent treatment decisions.
Once a diagnosis is confirmed, precise imaging is essential for Diagnosis and Staging. Staging defines the tumor’s size, nodal involvement, and distant spread, directly influencing therapeutic options.
Core imaging modalities include:
For patients with suspected central disease, endobronchial ultrasound (EBUS) and mediastinoscopy provide minimally invasive ways to sample mediastinal lymph nodes, clarifying nodal status (N stage). In cases where PET‑CT reveals distant lesions, additional targeted imaging—such as brain MRI—helps confirm metastatic spread (M stage).
Liv Hospital’s imaging department integrates these techniques into a seamless workflow, ensuring that each scan is scheduled promptly and interpreted by radiologists with oncology expertise. This rapid turnaround is especially valuable for international patients who may have limited time abroad.
Modern Diagnosis and Staging extend beyond anatomical assessment to include molecular profiling. Targeted therapies and immunotherapies rely on the identification of specific genetic alterations within the tumor.
Commonly evaluated biomarkers include:
Specimens obtained during biopsy are sent to our molecular pathology laboratory, where high‑throughput NGS platforms generate results within 7‑10 days. For patients traveling from abroad, we offer secure digital delivery of reports and virtual consultations with our thoracic oncology team to discuss findings and treatment implications.
In addition to DNA‑based testing, liquid biopsy (circulating tumor DNA) is available for patients who cannot undergo invasive procedures or for monitoring disease evolution during therapy. This non‑invasive approach complements tissue testing and can detect resistance mutations early, allowing timely adjustments to the treatment plan.
Accurate histopathology is a pivotal component of Diagnosis and Staging. After tissue acquisition, the sample undergoes a series of processes to determine tumor type, grade, and additional prognostic features.
Key steps include:
Liv Hospital’s pathology team follows international standards, including CAP (College of American Pathologists) and JCI guidelines, ensuring consistency and reliability. For international patients, reports are translated into multiple languages upon request, facilitating communication with referring physicians in the patient’s home country.
The final stage of lung cancer is assigned using the TNM system (Tumor, Node, Metastasis), a universally accepted framework that integrates anatomical and biological data. This classification directly informs treatment pathways—ranging from surgical resection to systemic therapy.
Typical staging workflow at Liv Hospital:
After data collection, the case is presented at a multidisciplinary tumor board comprising thoracic surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and nurse coordinators. The team reviews imaging, pathology, and molecular results to assign a stage (I‑IV) and formulate a personalized treatment plan.
Below is a simplified overview of the TNM categories for non‑small cell lung cancer (NSCLC):
Accurate staging ensures that patients receive the most effective therapy while avoiding overtreatment. For example, early‑stage (I‑II) disease may be cured with surgery or stereotactic radiotherapy, whereas stage IV disease typically requires systemic therapy combined with supportive care.
Traveling for lung cancer assessment introduces logistical considerations that can affect the smooth execution of Diagnosis and Staging. Liv Hospital’s dedicated International Patient Services team assists with every step, from visa arrangements to post‑procedure follow‑up.
Key support elements include:
All diagnostic procedures are performed in accredited facilities adhering to JCI standards, guaranteeing safety and quality. After the diagnostic work‑up, a detailed report—along with a personalized care plan—is shared electronically, allowing patients to coordinate follow‑up care with their home physicians if desired.
Liv Hospital combines JCI accreditation, cutting‑edge technology, and a multilingual care team to deliver a seamless diagnostic experience for lung cancer patients worldwide. Our integrated approach ensures that every step of Diagnosis and Staging—from imaging to molecular profiling—is performed with precision and compassion. International patients benefit from 360‑degree support, including visa assistance, interpreter services, and comfortable accommodation, allowing them to focus solely on their health journey.
Ready to take the next step in your lung cancer care? Contact Liv Hospital’s International Patient Services today to schedule your personalized diagnostic evaluation and experience world‑class oncology expertise in Istanbul.
Send us all your questions or requests, and our expert team will assist you.
Diagnosing lung cancer begins with a thorough review of the patient’s smoking history, occupational exposures, and family cancer background. A physical examination looks for symptoms such as persistent cough, chest pain, or weight loss. Imaging starts with a chest X‑ray for quick screening, followed by low‑dose computed tomography (LDCT) for higher‑risk individuals, which offers greater sensitivity. Pulmonary function tests assess lung capacity to determine surgical eligibility. If an abnormality is detected, tissue sampling via bronchoscopy, EBUS, or CT‑guided needle biopsy is performed to confirm malignancy and define histology.
Positron Emission Tomography combined with CT (PET‑CT) provides functional imaging that highlights areas of increased glucose metabolism, typical of cancer cells. This allows clinicians to identify metastatic lesions that may be missed on conventional CT, especially in lymph nodes and distant organs. By accurately mapping both the primary tumor and distant spread, PET‑CT helps assign a more precise N (nodal) and M (metastasis) stage, which directly influences treatment decisions such as surgery, radiotherapy, or systemic therapy.
Targeted and immunotherapies rely on identifying specific genetic alterations. EGFR mutations predict response to tyrosine kinase inhibitors, while ALK and ROS1 rearrangements indicate eligibility for corresponding inhibitors. KRAS mutations, though historically untargetable, now have emerging therapies and affect prognosis. PD‑L1 expression guides the use of immune checkpoint inhibitors. Comprehensive next‑generation sequencing panels can detect these and rarer alterations, enabling a personalized treatment plan. Liquid biopsy can also monitor these markers over time.
After all diagnostic data are collected—CT, PET‑CT, MRI, biopsy pathology, and molecular profiling—the case is presented to a multidisciplinary tumor board. This team includes thoracic surgeons, medical and radiation oncologists, radiologists, pathologists, and nurse coordinators. Together they interpret the findings, assign a TNM stage according to the latest guidelines, and decide on the optimal therapeutic pathway, whether surgical resection, stereotactic radiotherapy, systemic therapy, or palliative care. This collaborative approach ensures that every aspect of the patient’s disease is considered.
Liquid biopsy analyzes circulating tumor DNA (ctDNA) from a blood sample, offering a less invasive alternative to tissue biopsy. It is especially valuable for patients who cannot undergo invasive procedures due to health constraints or tumor location. ctDNA can reveal actionable mutations and resistance mechanisms, allowing clinicians to adjust therapy promptly. Moreover, serial liquid biopsies enable real‑time monitoring of disease progression or response to treatment, detecting emerging mutations before radiologic changes become apparent.
Your Comparison List (you must select at least 2 packages)
